Alternative splicing in the regulation of cholesterol homeostasis

Current Opinion in Lipidology

Volumn 24, Issue 2, 2013, Pages 147-152

  Medina, Marisa ^a   Krauss, Ronald ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; low density lipoprotein receptor; polypyrimidine tract binding protein 1; SFRS10; statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; MEVALONIC ACID; OMEGA 6 FATTY ACID; POLYPYRIMIDINE TRACT BINDING PROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALTERNATIVE RNA SPLICING; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; ANIMALS; CHOLESTEROL; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MUTATION; POLYPYRIMIDINE TRACT-BINDING PROTEIN; RNA STABILITY; RNA, MESSENGER;

EID: 84875220736     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835cf284     Document Type: Review

References (49)

1. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010; 463: 457-463.
2. Kelemen O, Convertini P, Zhang Z, et al. Function of alternative splicing. Gene 2012 [Epub ahead of print].
3. Sharp PA. Split genes and RNA splicing. Cell 1994; 77: 805-815.
4. Lee Y, Kim B, Shin Y, et al. ECgene: an alternative splicing database update. Nucleic Acids Res 2007; 35: D99-D103.
5. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001; 29: 2850-2859.
6. Johnson JM, Castle J, Garrett-Engele P, et al. Genome-wide survey of human alternative premRNA splicing with exon junction microarrays. Science 2003; 302: 2141-2144.
7. Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. NatGenet 2008; 40: 1413-1415.
8. Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476.
9. Holla OL, Nakken S, Mattingsdal M, et al. Effects of intronic mutations in the LDLR gene on premRNA splicing: comparison of wet-lab and bioinformatics analyses. Mol Genet Metab 2009; 96: 245-252.
10. Medina MW, Gao F, Naidoo D, et al. Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake. PLoS One 2011; 6: e19420. This is the first demonstration that key regulatory genes involved in cellular cholesterol homeostasis undergo regulated alternative splicing in response to the changes in cellular sterol content.
11. Tveten K, Ranheim T, Berge KE, et al. Analysis of alternatively spliced isoforms of human LDL receptor mRNA. Clin Chim Acta 2006; 373: 151-157.
12. Zhang X, Moor AN, Merkler KA, et al. Regulation of alternative splicing of liver scavenger receptor class B gene by estrogen and the involved regulatory splicing factors. Endocrinology 2007; 148: 5295-5304.
13. Skandalis A, Frampton M, Seger J, Richards MH. The adaptive significance of unproductive alternative splicing in primates. RNA 2010; 16: 2014-2022.
14. Hsu SN, Hertel KJ. Spliceosomes walk the line: splicing errors and their impact on cellular function. RNA Biol 2009; 6: 526-530.
15. Sorek R, Shamir R, Ast G. How prevalent is functional alternative splicing in the human genome? Trends Genet 2004; 20: 68-71.
16. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 2007; 76: 51-74.
17. Frischmeyer PA, van Hoof A, O'Donnell K, et al. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002; 295: 2258-2261.
18. Doma MK, Parker R. Endonucleolytic cleavage of eukaryotic mRNAs with stalls in translation elongation. Nature 2006; 440: 561-564.
19. Mudge JM, Frankish A, Fernandez-Banet J, et al. The origins, evolution, and functional potential of alternative splicing in vertebrates. Mol Biol Evol 2011; 28: 2949-2959.
20. Tress ML, Martelli PL, Frankish A, et al. The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci USA 2007; 104: 5495-5500.
21. Zhang Z, Xin D, Wang P, et al. Noisy splicing, more than expression regulation, explains why some exons are subject to nonsense-mediated mRNA decay. BMC Biol 2009; 7: 23.
22. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 2008; 33: 385-393.
23. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA 2003; 100: 189-192.
24. Sawicka K, Bushell M, Spriggs KA, Willis AE. Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans 2008; 36: 641-647.
25. Knoch KP, Meisterfeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in beta cells. Cell Metab 2006; 3: 123-134.
26. Reardon HT, Park WJ, Zhang J, et al. The polypyrimidine tract binding protein regulates desaturase alternative splicing and PUFA composition. J Lipid Res 2011; 52: 2279-2286. One of the first demonstrations that modulation of a splicing factor, in this case PTBP1, can modulate cellular lipid metabolism.
27. Dauwalder B, Amaya-Manzanares F, Mattox W. A human homologue of the Drosophila sex determination factor transformer-2 has conserved splicing regulatory functions. Proc Natl Acad Sci USA 1996; 93: 9004-9009.
28. Webb NR, Connell PM, Graf GA, et al. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem 1998; 273: 15241-15248.
29. Pihlajamaki J, Lerin C, Itkonen P, et al. Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab 2011; 14: 208-218. This study describes the identification of SFRS10, a splicing factor, associated with obesity and dyslipidemia, and specifically was the first study to demonstrate the metabolic impact of a splicing factor using an rodent model.
30. Brosch M, von Schonfels W, Ahrens M, et al. SFRS10-a splicing factor gene reduced in human obesity? Cell Metab 2012; 15: 265-266; author reply 267-269..
31. Pihlajamaki J, Lerin C, Kaminska D, et al. Response to Brosch et al. Cell Metab 2012; 15: 267-269.
32. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-713.
33. Burkhardt R, Kenny EE, Lowe JK, et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 2008; 28: 2078-2084.
34. Chung JY, Cho SK, Oh ES, et al. Effect of HMGCR variant alleles on lowdensity lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. J Clin Pharmacol 2012; 52: 339-346.
35. Poduri A, Khullar M, Bahl A, et al. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010; 29: 629-637.
36. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821-2827.
37. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117: 1537-1544.
38. Medina MW, Gao F, Ruan W, et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008; 118: 355-362.
39. Clendening JW, Pandyra A, Boutros PC, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 2010; 107: 15051-15056.
40. Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 2010; 3: 597-603.
41. Al-Khateeb A, Zahri MK, Mohamed MS, et al. Analysis of sequence variations in low-density lipoprotein receptor gene among Malaysian patients with familial hypercholesterolemia. BMC Med Genet 2011; 12: 40.
42. Basel-Vanagaite L, Zevit N, Har Zahav A, et al. Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am J Hum Genet 2012; 90: 49-60.
43. Ohtani R, Inazu A, Noji Y, et al. Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. Clin Chim Acta 2012; 413: 537-543.
44. Cefalu AB, Noto D, Magnolo L, et al. Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. Atherosclerosis 2009; 204: 202-207.
45. Pons V, Rolland C, Nauze M, et al. A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein (MTTP). Hum Mutat 2011; 32: 751-759.
46. Di Filippo M, Crehalet H, Samson-Bouma ME, et al. Molecular and functional analysis of two new MTTP gene mutations in an atypical case of abetalipoproteinemia. J Lipid Res 2012; 53: 548-555.
47. Koo G, Conley SK, Wassif CA, Porter FD. Discordant phenotype and sterol biochemistry in Smith-Lemli-Opitz syndrome. Am J Med Genet A 2010; 152A: 2094-2098.
48. Nair AK, Young MA, Menon KM. Regulation of luteinizing hormone receptor mRNA expression by mevalonate kinase-role of the catalytic center in mRNA recognition. FEBS J 2008; 275: 3397-3407.
49. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914.